

Daniel A Alcolea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4224543/publications.pdf>

Version: 2024-02-01

169
papers

9,114
citations

61984

43
h-index

49909

87
g-index

193
all docs

193
docs citations

193
times ranked

10955
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
3	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	12.4	600
4	TREM2 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	6.9	392
5	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.8	344
6	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
7	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	21.4	198
8	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.8	179
9	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2013, 74, 655-668.	5.3	171
10	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
11	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet</i> , The, 2020, 395, 1988-1997.	13.7	164
12	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 42 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016, 39, 2041-2048.	1.1	140
13	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	10.2	140
14	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
15	Association of Cerebral Amyloid- β 2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
16	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , 2015, 85, 626-633.	1.1	131
17	Dementia Risk in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 359-64.	4.5	125
18	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.8	122

#	ARTICLE	IF	CITATIONS
19	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	4.0	119
20	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	3.8	115
21	Cerebrospinal fluid β -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 223-230.	5.3	110
22	Relationship Between β -Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 157-167.	2.6	106
23	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	3.7	104
24	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013, 125, 201-213.	7.7	103
25	CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.1	100
26	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , 2014, 23, 749-754.	2.9	98
27	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
28	<i>APOE</i> -by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015, 6, 26663-26674.	1.8	92
29	A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.7	87
30	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
31	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in prodementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2018-2023.	3.1	75
32	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	3.7	70
33	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 499-509.	0.8	65
34	Neuropsychological deficits in patients with cognitive complaints after COVID-19. <i>Brain and Behavior</i> , 2022, 12, e2508.	2.2	64
35	Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 807-812.	2.8	63
36	CSF sAPP β , YKL-40, and NfL along the ALS-FTD spectrum. <i>Neurology</i> , 2018, 91, e1619-e1628.	1.1	59

#	ARTICLE	IF	CITATIONS
37	Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 609.	2.8	59
38	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
39	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018, 9, 34691-34698.	1.8	57
40	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015, 138, e400-e400.	7.6	56
41	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	1.9	55
42	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	54
43	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 67-77.	2.6	53
44	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 719-726.	2.6	53
45	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017, 8, 104706-104716.	1.8	51
46	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	14.8	48
47	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.8	47
48	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	5.9	47
49	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.8	46
50	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	4.0	45
51	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	7.6	45
52	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	3.7	44
53	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
54	Cerebrospinal Fluid Anti-Amyloid- β 2 Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1-7.	2.6	43

#	ARTICLE	IF	CITATIONS
55	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid- β Peptide Aggregation. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 643-657.	2.6	41
56	Rapidly Progressive Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 267-271.	1.3	40
57	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 70-77.	1.9	40
58	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 710-717.	4.3	39
59	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 539-546.	2.6	38
60	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	2.4	37
61	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.8	34
62	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	3.3	33
63	Cerebrospinal fluid A β 40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	6.2	33
64	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	12.8	33
65	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	9.0	32
66	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	8.0	32
67	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	3.1	30
68	Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2020, 92, 7-11.	3.1	30
69	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	1.9	30
70	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	10.2	29
71	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 909-918.	2.6	28
72	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27

#	ARTICLE	IF	CITATIONS
73	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.8	27
74	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
75	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. <i>Cerebral Cortex</i> , 2020, 30, 2083-2098.	2.9	25
76	Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12047.	2.4	25
77	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	2.6	25
78	The Effect of MAPT H1 and APOE ϵ 4 on Transition from Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1065-1071.	2.6	24
79	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017, 53, 192.e1-192.e4.	3.1	24
80	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	6.1	24
81	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.8	23
82	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.8	22
83	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	10.8	21
84	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	3.4	20
85	Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. <i>Neurology</i> , 2020, 95, e2565-e2576.	1.1	19
86	Annexin A5 prevents amyloid- β -induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 9391.	3.3	18
87	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	2.6	18
88	The A β ₁₋₄₂ /A β ₁₋₄₀ ratio in CSF is more strongly associated to tau markers and clinical progression than A β ₁₋₄₂ alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	6.2	18
89	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019, 490, 98-101.	1.1	17
90	Elevated YKL-40 and low sAPP β :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	1.9	17

#	ARTICLE	IF	CITATIONS
91	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	7.6	17
92	Remote cerebral hematomas in patients treated with intravenous rt-PA. <i>Journal of Neurology</i> , 2010, 257, 1062-1066.	3.6	16
93	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 505-513.	2.6	16
94	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1489-1496.	2.6	14
95	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2012, 33, 1851.e17-1851.e19.	3.1	13
96	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 175-180.	1.7	13
97	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	3.7	13
98	Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders. <i>Cell Metabolism</i> , 2022, 34, 269-284.e9.	16.2	13
99	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	4.1	13
100	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12
101	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	5.9	12
102	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021, 17, 1499-1508.	0.8	11
103	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 469-476.	1.9	10
104	Heterozygous <i>APOE</i> Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 579-582.	3.2	10
105	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	6.2	10
106	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	2.5	9
107	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 353-356.	1.3	8
108	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 58-67.	3.1	8

#	ARTICLE	IF	CITATIONS
109	The cognitive aftermath of COVID-19. <i>Brain Communications</i> , 2020, 2, .	3.3	8
110	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 37.	8.0	8
111	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 1252.	4.1	8
112	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1327-1333.	2.6	7
113	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	2.4	7
114	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	2.6	7
115	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001516.	2.8	7
116	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	5.3	7
117	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicines</i> , 2021, 9, 1610.	3.2	7
118	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	2.8	7
119	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	10.8	7
120	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	7
121	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	6.2	6
122	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. <i>Frontiers in Neurology</i> , 2021, 12, 750543.	2.4	6
123	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	2.6	5
124	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017, 13, 1072-1074.	0.8	5
125	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 160.	6.2	5
126	O5a02a04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2016, 12, P380.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	4
128	Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1058-1063.	2.3	4
129	[O3-10-03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.	0.8	3
130	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2
131	Effect of REST on brain metabolism in the Alzheimer disease continuum. <i>Annals of Neurology</i> , 2015, 78, 661-662.	5.3	2
132	P1-277: CORRELATION BETWEEN INNOTEST® AND THE FULLY AUTOMATED LUMIPULSE® G PLATFORM FOR THE ANALYSIS OF Aβ42 AND TOTAL TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P388.	0.8	1
133	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.8	1
134	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.8	1
135	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 176.	6.2	1
136	Calsyntenin1 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
137	P3-230: CSF Aβ-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
138	IC-P-217: CSF Aβ-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
139	Reply. <i>Annals of Neurology</i> , 2014, 75, 460-461.	5.3	0
140	P2-121: CHARACTERIZATION OF THE CEREBROSPINAL FLUID PROTEOME IN THE SEARCH FOR BIOMARKERS OF PRECLINICAL AD. , 2014, 10, P515-P515.		0
141	P2-088: RELATIONSHIP BETWEEN CSF YKL-40 AND CORTICAL THICKNESS. , 2014, 10, P503-P503.		0
142	P2-132: BIOMARKERS IN CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION. , 2014, 10, P519-P519.		0
143	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. <i>Alzheimer's and Dementia</i> , 2016, 12, P1059.	0.8	0
144	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0

#	ARTICLE	IF	CITATIONS
145	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
146	[P1â€“366]: WEIGHT LOSS MIGHT BE A NONâ€“COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.8	0
147	[P3â€“274]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. Alzheimer's and Dementia, 2017, 13, P1048.	0.8	0
148	[P1â€“238]: THE SAPPÎ ² /YKLâ€“40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P335.	0.8	0
149	[P4â€“505]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER. Alzheimer's and Dementia, 2017, 13, P1533.	0.8	0
150	[P2â€“259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR ADâ€“RELATED SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P712.	0.8	0
151	P4â€“076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P1463.	0.8	0
152	P2â€“262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
153	P3â€“394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
154	P1â€“293: IDENTIFICATION OF EXOSOMAL MICRORNAs AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.8	0
155	ICâ€“Pâ€“148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P119.	0.8	0
156	O2â€“09â€“01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P558.	0.8	0
157	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. Alzheimer's and Dementia, 2020, 16, e041255.	0.8	0
158	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. Alzheimer's and Dementia, 2020, 16, e041500.	0.8	0
159	The effect of APOE É4 in Alzheimerâ€™s disease biomarkers in Down syndrome. Alzheimer's and Dementia, 2020, 16, e042889.	0.8	0
160	1 Hâ€“MRS signature in Alzheimer disease in Down syndrome. Alzheimer's and Dementia, 2020, 16, e043346.	0.8	0
161	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. Alzheimer's and Dementia, 2020, 16, e044772.	0.8	0
162	Which preâ€“analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. Alzheimer's and Dementia, 2020, 16, e045060.	0.8	0

#	ARTICLE	IF	CITATIONS
163	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045268.	0.8	0
164	Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047017.	0.8	0
165	Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The Fundaci3 ACE Biomarker Research Program (FACEBREP). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
166	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
167	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
168	Neuropsychological correlates of plasma NfL in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
169	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0